Novartis announced data from subgroup analyses of the three pivotal phase III MONALEESA trials showing that Kisqali (ribociclib) plus endocrine therapy extended progression-free survival compared to endocrine therapy alone, regardless of the presence of visceral metastases in pre-, peri- and postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
